Pharma News

Novartis drug Afinitor extends progression-free survival in patients with advanced pancreatic neuroendocrine tumors

The New England Journal of Medicine (NEJM) published a study that shows Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival (PFS), or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET)[1].

FDA Adds 13 Drugs to Watch List

The US Food and Drug Administration (FDA) has released its latest list of drugs to monitor based on potential signs of serious risks or new safety information identified in the agency's Adverse Event Reporting System (AERS).

The quarterly watch list consists of 13 medications that treat a wide range of conditions, including cough, angina, diabetes, cancer, and bipolar disorder.

Researchers from UTHealth & Athersys present data illustrating potential benefits of MultiStem for treating stroke

Medical researchers from The University of Texas Health Science Centre at Houston (UTHealth) presented new research results at the American Heart Association International Stroke Conference that demonstrated how MultiStem, a novel stem cell therapy being developed by Athersys, Inc. provided multiple benefits when administered in preclinical models of ischemic stroke.

Pages